SG171592A1 - Method of inhibiting c-kit kinase - Google Patents

Method of inhibiting c-kit kinase

Info

Publication number
SG171592A1
SG171592A1 SG201102829-7A SG2011028297A SG171592A1 SG 171592 A1 SG171592 A1 SG 171592A1 SG 2011028297 A SG2011028297 A SG 2011028297A SG 171592 A1 SG171592 A1 SG 171592A1
Authority
SG
Singapore
Prior art keywords
inhibiting
kit
kit kinase
subject
present
Prior art date
Application number
SG201102829-7A
Other languages
English (en)
Inventor
Carl R Illig
Shelley K Ballentine
Jingsheng Chen
Sanath K Meegalla
Mark J Wall
Kenneth J Wilson
M Jonathan Rudolph
Renee L Desjarlais
Christopher J Molloy
Carl L Manthey
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG171592A1 publication Critical patent/SG171592A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG201102829-7A 2006-04-20 2007-04-19 Method of inhibiting c-kit kinase SG171592A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79347106P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
SG171592A1 true SG171592A1 (en) 2011-06-29

Family

ID=38625740

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102829-7A SG171592A1 (en) 2006-04-20 2007-04-19 Method of inhibiting c-kit kinase

Country Status (21)

Country Link
EP (2) EP2397138B1 (enExample)
JP (1) JP5595727B2 (enExample)
KR (1) KR101448052B1 (enExample)
CN (2) CN102670605B (enExample)
AU (1) AU2007240400B2 (enExample)
BR (1) BRPI0710542B8 (enExample)
CA (1) CA2649755C (enExample)
CO (1) CO6382175A2 (enExample)
CR (1) CR10450A (enExample)
EA (1) EA016611B1 (enExample)
EC (1) ECSP088842A (enExample)
ES (2) ES2458291T3 (enExample)
GT (1) GT200800225A (enExample)
IL (1) IL194846A (enExample)
MX (1) MX2008013528A (enExample)
MY (1) MY147226A (enExample)
NO (1) NO342001B1 (enExample)
NZ (1) NZ572200A (enExample)
SG (1) SG171592A1 (enExample)
WO (1) WO2007124369A2 (enExample)
ZA (1) ZA200809874B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014001977A2 (pt) 2011-07-27 2017-02-21 Ab Science inibidores seletivos de proteína quinase
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
CN105658649B (zh) 2013-07-22 2019-03-22 爱杜西亚药品有限公司 1-(哌嗪-1-基)-2-([1,2,4]三唑-1-基)-乙酮衍生物
PE20171100A1 (es) 2015-01-15 2017-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
CN105753770A (zh) * 2015-05-27 2016-07-13 上海佐林生物医药有限公司 蛋白激酶抑制剂制备方法、中间体、制备方法及应用
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
ATE375342T1 (de) * 2002-08-02 2007-10-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
US7718676B2 (en) * 2003-10-23 2010-05-18 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
NZ548884A (en) * 2004-01-30 2010-06-25 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
BRPI0516947A (pt) * 2004-10-22 2008-09-23 Janssen Pharmaceutica Nv inibidores de quinase c-fms
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006304897B2 (en) * 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
NZ572072A (en) * 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
WO2007124316A1 (en) * 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
EP2016057A1 (en) * 2006-04-20 2009-01-21 Janssen Pharmaceutica N.V. C-fms kinase inhibitors

Also Published As

Publication number Publication date
JP2009534418A (ja) 2009-09-24
EP2397138A1 (en) 2011-12-21
IL194846A0 (en) 2009-08-03
MX2008013528A (es) 2008-10-29
CN102670605A (zh) 2012-09-19
EA016611B1 (ru) 2012-06-29
KR20080111545A (ko) 2008-12-23
AU2007240400B2 (en) 2013-08-22
WO2007124369A3 (en) 2008-03-06
CA2649755C (en) 2014-12-02
ZA200809874B (en) 2010-02-24
EP2015748B1 (en) 2012-07-04
CR10450A (es) 2009-02-23
CA2649755A1 (en) 2007-11-01
EP2397138B1 (en) 2013-12-11
WO2007124369A2 (en) 2007-11-01
EP2015748A2 (en) 2009-01-21
BRPI0710542A2 (pt) 2012-06-05
IL194846A (en) 2015-07-30
CN101610768A (zh) 2009-12-23
BRPI0710542B8 (pt) 2021-05-25
ES2389678T3 (es) 2012-10-30
KR101448052B1 (ko) 2014-10-07
MY147226A (en) 2012-11-14
CN102670605B (zh) 2015-07-29
NO342001B1 (no) 2018-03-12
AU2007240400A1 (en) 2007-11-01
CO6382175A2 (es) 2012-02-15
GT200800225A (es) 2009-05-15
HK1124766A1 (en) 2009-07-24
NZ572200A (en) 2011-09-30
ECSP088842A (es) 2008-11-27
JP5595727B2 (ja) 2014-09-24
CN101610768B (zh) 2012-03-21
NO20084892L (no) 2009-01-06
EA200870454A1 (ru) 2009-04-28
BRPI0710542B1 (pt) 2021-01-12
ES2458291T3 (es) 2014-04-30

Similar Documents

Publication Publication Date Title
WO2007048088A3 (en) Method of inhibiting flt3 kinase
SG171592A1 (en) Method of inhibiting c-kit kinase
MX2009009786A (es) Inhibidores de la via de hedgehog.
MY161576A (en) Quinazoline derivatives as raf kinase modulators and methods of use thereof
NZ708563A (en) Treatment of cancers using pi3 kinase isoform modulators
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2010004263A (es) Inhibidores de quinasa c-fms.
MX2010003668A (es) Derivados de purina sustituidas con primidina.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX2009013077A (es) Derivados dde benzoxazolona.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009003941A (es) Derivados de 3-(dihidro-1h-pirazolo[4,3-d]pirimidin-5-il)-4-propox ibencenosulfonamida y metodos de uso.
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
MX2011007165A (es) Derivados de piridazinona.
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
MX2011012522A (es) Inhibidores de pirazol sustituido de proteina cinasa c-met.
UA106082C2 (uk) АМІНОПІРАЗОЛ ТРИАЗОЛОТІАДІАЗОЛЬНІ ІНГІБІТОРИ ПРОТЕЇНКІНАЗИ c-МЕТ
MX2011012524A (es) Inhibidores de proteina cinasa c-met.